These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 37967254)

  • 21. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.
    Stadtmauer EA; Sullivan KM; El Idrissi M; Salaun B; Alonso Alonso A; Andreadis C; Anttila VJ; Bloor AJ; Broady R; Cellini C; Cuneo A; Dagnew AF; Di Paolo E; Eom H; González-Rodríguez AP; Grigg A; Guenther A; Heineman TC; Jarque I; Kwak JY; Lucchesi A; Oostvogels L; Polo Zarzuela M; Schuind AE; Shea TC; Sinisalo UM; Vural F; Yáñez San Segundo L; Zachée P; Bastidas A
    Hum Vaccin Immunother; 2021 Nov; 17(11):4144-4154. PubMed ID: 34406911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.
    López-Fauqued M; Campora L; Delannois F; El Idrissi M; Oostvogels L; De Looze FJ; Diez-Domingo J; Heineman TC; Lal H; McElhaney JE; McNeil SA; Yeo W; Tavares-Da-Silva F;
    Vaccine; 2019 Apr; 37(18):2482-2493. PubMed ID: 30935742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Fix J; Vielot NA; Lund JL; Weber DJ; Smith JS; Hudgens MG; Becker-Dreps S
    Vaccine; 2023 Jan; 41(1):49-60. PubMed ID: 36396511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant Zoster Vaccine (Shingrix
    Syed YY
    Drugs Aging; 2018 Dec; 35(12):1031-1040. PubMed ID: 30370455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
    Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine.
    Tavares-Da-Silva F; Co MM; Dessart C; Hervé C; López-Fauqued M; Mahaux O; Van Holle L; Stegmann JU
    Vaccine; 2020 Apr; 38(18):3489-3500. PubMed ID: 31818534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
    Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting.
    Zerbo O; Bartlett J; Fireman B; Lewis N; Goddard K; Dooling K; Duffy J; Glanz J; Naleway A; Donahue JG; Klein NP
    Ann Intern Med; 2024 Feb; 177(2):189-195. PubMed ID: 38190712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US.
    Leung J; Anderson TC; Dooling K; Xie F; Curtis JR
    Arthritis Rheumatol; 2022 Nov; 74(11):1833-1841. PubMed ID: 35666070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
    Curran D; Kim JH; Matthews S; Dessart C; Levin MJ; Oostvogels L; Riley ME; Schmader KE; Cunningham AL; McNeil SA; Schuind AE; Andrew MK;
    J Am Geriatr Soc; 2021 Mar; 69(3):744-752. PubMed ID: 33197294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.
    Hentzien M; Bonnet F; Bernasconi E; Biver E; Braun DL; Munting A; Leuzinger K; Leleux O; Musardo S; Prendki V; Schmid P; Staehelin C; Stoeckle M; Walti CS; Wittkop L; Appay V; Didierlaurent AM; Calmy A
    BMC Infect Dis; 2024 Mar; 24(1):329. PubMed ID: 38504173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged ≥50 years in the United States.
    Florea A; Sy L; Qian L; Ackerson B; Luo Y; Wu J; Cheng Y; Ku J; Vega Daily L; Takhar H; Song J; Chmielewski-Yee E; Spence O; Seifert H; Oraichi D; Tseng HF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2327145. PubMed ID: 38488143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the Link between Varicella-Zoster Virus, Autoimmune Diseases, and the Role of Recombinant Zoster Vaccine.
    Ishihara R; Watanabe R; Shiomi M; Katsushima M; Fukumoto K; Yamada S; Okano T; Hashimoto M
    Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
    Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
    J Virol; 2021 May; 95(12):. PubMed ID: 33762414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
    Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL
    Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients.
    George S; Regan J; Awan A; O'Connor M; Foster A; Raymond K; Gorfinkel I; McNeil SA
    Hum Vaccin Immunother; 2024 Dec; 20(1):2317595. PubMed ID: 38502342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.